Literature DB >> 14698283

The lung as a privileged site for the beneficial actions of PGE2.

Carlo Vancheri1, Claudio Mastruzzo, Maria Angela Sortino, Nunzio Crimi.   

Abstract

Prostaglandin E2 (PGE2) is commonly considered a potent proinflammatory mediator and is involved in several inflammatory diseases. In the lung, as opposed to many other parts of the body, PGE2 has a role in limiting the immune-inflammatory response as well as tissue repair processes. Understanding the full implications of the regulatory role of PGE2 and how beneficial processes, such as inflammation and tissue repair, become dysregulated to the point of causing disease, might disclose new perspectives in the treatment of pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698283     DOI: 10.1016/j.it.2003.11.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  105 in total

Review 1.  Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes.

Authors:  Gary A Weisman; M Wang; Q Kong; N E Chorna; J T Neary; Grace Y Sun; Fernando A González; C I Seye; L Erb
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

2.  Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation.

Authors:  Linda J Kay; Wilfred W Yeo; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

3.  Selective eicosanoid-generating capacity of cytoplasmic phospholipase A2 in Pseudomonas aeruginosa-infected epithelial cells.

Authors:  Bryan P Hurley; Waheed Pirzai; Karen L Mumy; Karsten Gronert; Beth A McCormick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

Review 4.  G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation.

Authors:  Hye Sun Kuehn; Alasdair M Gilfillan
Journal:  Immunol Lett       Date:  2007-09-18       Impact factor: 3.685

Review 5.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

6.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

7.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

8.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

Review 9.  Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling.

Authors:  Yutong Zhao; Viswanathan Natarajan
Journal:  Cell Signal       Date:  2008-10-26       Impact factor: 4.315

10.  Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts.

Authors:  Takayoshi Matsumura; Toru Suzuki; Kenichi Aizawa; Daigo Sawaki; Yoshiko Munemasa; Junichi Ishida; Ryozo Nagai
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.